Evommune (EVMN) Cash from Financing Activities (2024 - 2026)
Evommune (EVMN) posted quarterly Cash from Financing Activities of $117.1 million for Q1 2026, up 77146.71% year-over-year from N/an in Q1 2025, and down 25.33% quarter-over-quarter from $156.8 million in Q4 2025.
Powered by 
Analysis
Evommune (EVMN) Cash from Financing Activities (2024 - 2026) Analysis & Trends
Evommune (EVMN) has reported Cash from Financing Activities for 3 consecutive years, with $117.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 77146.71% year-over-year to $117.1 million; the TTM figure through Mar 2026 stood at $323.5 million (changed N/A YoY), while the FY2025 annual figure was $220.8 million, up 346.72% from the prior year.
- Cash from Financing Activities retreated to $117.1 million in Q1 2026 per EVMN's latest filing, from $156.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $156.8 million in Q4 2025 and bottomed at -$152000.0 in Q1 2025.
- Historically, Cash from Financing Activities has averaged $80.9 million across 3 years, with a median of $83.4 million in 2024.
- Annual changes were most pronounced in 2025 — Cash from Financing Activities surged 215.58% — and 2026, when it jumped 77146.71%.
- Evommune's Cash from Financing Activities stood at $49.7 million in 2024, then soared by 215.58% to $156.8 million in 2025, then slipped by 25.33% to $117.1 million in 2026.
- Business Quant data shows EVMN's Cash from Financing Activities at $117.1 million in Q1 2026, $156.8 million in Q4 2025, and -$152000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Evommune | 445.19 Mn | 244.40 Mn | - | 532,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 532,000.00 |
| Mar 31, 2026 | 117.11 Mn |
| Dec 31, 2025 | 156.85 Mn |
| Sep 30, 2025 | -274,000.00 |
| Jun 30, 2025 | 64.34 Mn |
| Mar 31, 2025 | -152,000.00 |
| Dec 31, 2024 | 49.70 Mn |